1. I think the article is a little one sided in their explanation of the rebate system, though it certainly more opaque than it should be. (some of which is just healthtech is stuck in the dark ages)
2. The rebates really only apply to the branded meds, which are approximately 20% of the market.
1. I think the article is a little one sided in their explanation of the rebate system, though it certainly more opaque than it should be. (some of which is just healthtech is stuck in the dark ages)
2. The rebates really only apply to the branded meds, which are approximately 20% of the market.